• SEGG Media’s $14 million David Lloyd partnership brings premium sports infrastructure to U.S. market with projected $6 million first-year EBITDA from 100,000 square-foot Boca Raton facility
• Strategic motorsport sponsorships across IndyCar and Indy NXT create high-visibility brand exposure for Sports.com and Lottery.com through racing’s most competitive circuits
• Company’s three-vertical approach spanning sports, entertainment, and gaming positions SEGG at the intersection of rapidly converging digital entertainment markets

The sports entertainment industry is experiencing a fundamental shift that extends far beyond traditional broadcasting and venue management. As digital engagement becomes increasingly sophisticated, companies are discovering that success requires more than single-platform dominance; it demands integrated ecosystems that connect physical experiences with digital communities across multiple touchpoints.

This convergence creates both opportunity and complexity. Organizations attempting to bridge sports, entertainment, and gaming often struggle with fragmented approaches that fail to leverage synergies between verticals. The challenge lies in creating authentic connections between physical sports experiences and digital engagement platforms while maintaining brand coherence across diverse audience segments.

Most companies in this space operate with siloed strategies: sports properties focus on live events, gaming companies prioritize digital experiences, and entertainment brands emphasize content creation. This compartmentalized approach prevents organizations from capturing the full value of cross-vertical integration, where insights and audiences from one area can enhance performance and engagement in others.

The companies that successfully navigate this convergence are those that understand a critical market insight: the most valuable experiences are those that create seamless integration between physical and digital engagement, where each vertical reinforces and amplifies the others.

This represents the strategic positioning that SEGG Media (NASDAQ: SEGG) has developed through its multi-vertical approach to sports, entertainment, and gaming.

Premium Infrastructure Strategy Creates Physical Foundation

SEGG Media’s $14 million partnership with David Lloyd represents more than facility acquisition, it establishes a scalable model for premium sports infrastructure that bridges physical and digital experiences. The binding Letter of Intent for The Sports.com All-Sports Arena by David Lloyd in Boca Raton creates the first U.S. entry point for one of Europe’s most recognizable wellness brands.

The 100,000 square-foot facility combines state-of-the-art sporting infrastructure with cutting-edge co-working and business amenities. Key features include indoor padel, basketball, and pickleball courts, climbing walls, AI-driven golf simulators, and a full-service premium gymnasium designed to David Lloyd’s specifications. The facility also incorporates approximately 10,000 square feet of luxury co-working space inspired by Dubai’s successful “Nook” model.

“This is more than just a gym – it’s a sports and business ecosystem,” said Matthew McGahan, Chairman and CEO of SEGG Media. The facility’s design reflects understanding that modern sports entertainment requires integrated experiences that serve multiple audience segments simultaneously.

David Lloyd’s projections indicate the Boca facility will deliver over $6 million in EBITDA in its first year of operations, demonstrating the financial viability of the premium sports infrastructure model. The partnership establishes foundation for expansion across major U.S. cities and the Middle East, leveraging Sports.com’s global digital audience with David Lloyd’s operational excellence.

Motorsport Sponsorship Delivers High-Impact Brand Visibility

SEGG Media’s strategic sponsorship of IndyCar and Indy NXT drivers creates sustained brand exposure across North America’s most competitive racing circuits. The company’s support of drivers including Louis Foster, Callum Ilott, and Seb Murray generates consistent visibility for Sports.com and Lottery.com brands through on-car branding, in-paddock engagement, and major television coverage.

Louis Foster’s performance at Iowa Speedway exemplifies the strategic value of motorsport partnerships. The 21-year-old maintained his lead in the Rookie of the Year standings while delivering consistent results across both races, with his oval average now standing at 13.33. Foster’s breakthrough performances create authentic brand association with rising talent in one of motorsport’s most prestigious series.

The motorsport strategy extends beyond individual race results to create season-long narrative arcs that maintain audience engagement. Foster’s stellar drive performance will be celebrated in separate releases, demonstrating SEGG Media’s commitment to leveraging racing success for sustained brand building.

“Louis, Callum, and Seb continue to elevate the visibility and value of our brands across North America,” said Matthew McGahan. The Toronto Street circuit provides the next stage for continued brand expansion, combining tight city corners, passionate fans, and global media presence.

Three-Vertical Integration Creates Scalable Growth Platform

SEGG Media’s approach to sports, entertainment, and gaming convergence reflects understanding that modern audiences expect integrated experiences rather than standalone offerings. The company’s rebranding from Lottery.com to SEGG Media Corporation signals strategic evolution toward multi-vertical leadership.

The structure maintains Lottery.com as a key component within the gaming vertical, while integrating Sports.com and Concerts.com under unified corporate strategy. This approach enables cross-pollination of audiences and insights while maintaining brand distinction across different market segments.

The timing of this integration appears strategically advantageous. As digital entertainment boundaries continue blurring, companies that successfully bridge physical and digital experiences will capture disproportionate value. SEGG Media’s combination of premium infrastructure, motorsport partnerships, and gaming capabilities creates multiple revenue streams that can scale across global markets.

Global Expansion Strategy and Market Positioning

The David Lloyd partnership establishes a template for international expansion that combines brand recognition with operational excellence. David Lloyd’s legacy includes founding David Lloyd Leisure in 1982, which now operates 130 premium health, fitness and racquets clubs across Europe, serving over 710,000 members.

This rollout strategy positions SEGG Media to capitalize on the growing demand for premium sports experiences that integrate physical and digital engagement. The model’s scalability enables high margin returns through unique blend of sport, wellness, community, and entrepreneurship.

The motorsport partnerships provide consistent brand exposure across multiple markets while the gaming vertical creates digital touchpoints that extend engagement beyond physical locations. This integrated approach addresses the fundamental challenge facing sports entertainment companies: creating authentic connections between physical experiences and digital communities.

For more information, visit the company’s website at SEGGMediaCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to SEGG are available in the company’s newsroom at https://ibn.fm/SEGG

• FDA grants Type C Meeting for AVERSA(TM) Fentanyl to discuss Chemistry, Manufacturing, and Controls pathway from IND submission through NDA approval and commercialization
• CEO Gareth Sheridan temporarily steps aside to pursue Irish Presidential nomination while Chairman Serguei Melnik assumes interim CEO role during critical development phase
• Strategic partnership with Kindeva combines proven FDA-approved fentanyl patch technology with Nutriband’s proprietary abuse-deterrent platform targeting $80-200 million peak U.S. market opportunity

The pharmaceutical development landscape presents a fundamental shift as regulatory frameworks evolve beyond traditional efficacy-first approaches. The most significant patient impact now comes from innovations that enhance safety profiles of existing therapeutic options, particularly in pain management where the balance between therapeutic benefit and abuse potential creates urgent medical need alongside substantial regulatory complexity.

The opioid crisis has reshaped how regulators approach pain management solutions. The most promising opportunities exist at the intersection of proven therapeutic benefit and enhanced safety mechanisms, requiring both technological innovation and regulatory expertise to navigate complex approval pathways while maintaining operational continuity.

This convergence creates opportunities for companies like Nutriband (NASDAQ: NTRB), a transdermal pharmaceutical developer that has secured crucial FDA engagement for its lead abuse-deterrent technology while demonstrating organizational resilience through strategic leadership transitions.

Regulatory Validation Opens Clear Development Pathway

Nutriband’s FDA Type C Meeting approval for AVERSA(TM) Fentanyl signals agency recognition of the product’s potential to address critical unmet medical needs. The September 18 meeting with the Division of Anesthesiology, Addiction Medicine, and Pain Medicine focuses on Chemistry, Manufacturing, and Controls (“CMC”) plans spanning the entire development and commercialization timeline.

This milestone addresses the complete development arc from IND submission through 505(b)(2) NDA approval. The 505(b)(2) pathway allows Nutriband to leverage existing fentanyl safety data while focusing regulatory review on novel abuse-deterrent components.

The meeting’s scope, covering manufacturing through commercialization, indicates FDA willingness to engage on practical implementation, suggesting confidence in the technology and development approach.

Strategic Partnership Amplifies Development Capabilities

Nutriband’s collaboration with Kindeva Drug Delivery leverages strategic positioning by combining Nutriband’s proprietary Aversa technology with Kindeva’s FDA-approved fentanyl patch. This partnership accelerates development while maintaining innovative differentiation.

Kindeva brings established manufacturing processes and regulatory relationships, while Nutriband contributes breakthrough abuse-deterrent technology protected by patents in 46 countries. The global intellectual property portfolio creates sustainable competitive positioning extending beyond initial US market penetration.

With peak annual US sales projections of $80-200 million, international expansion represents substantial additional opportunity in markets facing similar pain management and abuse deterrence challenges.

Leadership Continuity Demonstrates Organizational Depth

CEO Gareth Sheridan’s temporary departure to pursue the Irish Presidential nomination showcases organizational strength through seamless transition to Chairman Serguei Melnik as interim CEO. Melnik’s background combines corporate strategy expertise with over 20 years of capital markets experience, aligning with Nutriband’s progression toward 2026 NDA filing targets.

Sheridan’s confidence in stepping aside during this critical phase reflects organizational maturity. His statement that “our tight knit team is really our core asset” suggests institutional knowledge that transcends individual leadership, crucial for navigating complex regulatory pathways.

Platform Technology Creates Scalable Opportunity

Aversa’s abuse-deterrent technology establishes a platform applicable across multiple transdermal applications. The technology incorporates aversive agents into patches preventing abuse, diversion, and accidental exposure while maintaining therapeutic accessibility.

This platform creates value beyond fentanyl applications. As regulatory focus on abuse deterrence expands across opioid and stimulant categories, Aversa technology could address similar challenges in other high-risk medications. The transdermal delivery method offers inherent abuse deterrence advantages compared to oral formulations.

Current regulatory dynamics favor abuse-deterrent innovations. Heightened opioid safety focus, combined with recognition of legitimate pain management needs, creates receptive environments for technologies enhancing safety without compromising efficacy.

Nutriband represents convergence of technological innovation, regulatory validation, and market timing defining compelling risk-adjusted return potential.

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

• In recent years, the number of golf trials, or first-time participants taking the game to the course, has hit remarkable levels.
• This expanding golf community creates an ideal market environment for innovative and quality-driven golf-equipment companies such as Newton Golf.
• Newton Golf is focused on bridging the gap between the casual golfer and the competitive player by offering equipment that supports progression.

The surge in golf’s popularity has created an unprecedented opportunity for companies such as Newton Golf Company (NASDAQ: NWTG), which is committed to providing high-quality golf equipment for players ranging from beginners to seasoned professionals. As the sport experiences record or near-record numbers of on-course beginners each year, Newton Golf stands poised to support and equip a rapidly expanding base of golf enthusiasts.

In recent years, the number of golf trials, or first-time participants taking the game to the course, has hit remarkable levels, with more than three million new on-course beginners annually since 2020 (https://ibn.fm/m7IoB). According to the National Golf Foundation’s research, this surge reflects a growing interest in golf across diverse demographics, driven by factors such as increased accessibility, social engagement and the health benefits associated with the sport. This influx is significant not only because it introduces new participants to the game but also because it fuels long-term growth by expanding the pipeline of future golf consumers.

These trial players represent the foundation of the golf industry’s revitalization, ensuring a steady flow of new players who may eventually become committed golfers, club members and equipment buyers. The National Golf Foundation’s data reveals that nearly 3.5 million people took up golf for the first time in 2021, and the figure remained strong in 2022 and 2023. This trend is supported by the growing participation in driving ranges, golf lessons and beginner-friendly golf programs nationwide. Industry experts note that converting these trials into regular players is essential for sustained growth, which in turn benefits golf courses, retailers and manufacturers alike.

This expanding golf community creates an ideal market environment for innovative and quality-driven golf-equipment companies such as Newton Golf. Established with the vision of making the game more accessible and enjoyable, Newton Golf focuses on designing clubs and gear that cater to all skill levels. The company’s approach combines advanced technology, ergonomic design and affordability to help players improve their game regardless of experience. The company’s product range includes beginner sets, intermediate clubs and custom options tailored for advanced players, reflecting its commitment to inclusivity within the sport.

Newton Golf is focused on bridging the gap between the casual golfer and the competitive player by offering equipment that supports progression. By investing in research and development, Newton continually integrates performance-enhancing features in its products, such as optimized shaft technologies and clubhead designs that improve consistency and power. This technical innovation aligns with the company’s dedication to empowering golfers to enjoy the game more fully while advancing their skills.

In addition, Newton Golf’s emphasis on community engagement and education aligns closely with the broader industry trend of growing participation through trials. The company partners with golf programs and driving ranges to promote beginner-friendly experiences, ensuring that new players have access to quality equipment from the outset. This strategy not only builds brand loyalty but also contributes to the overall health of the golf market by supporting the journey from trial to lifelong participation.

In a golf industry marked by renewed enthusiasm and rising participation numbers, Newton Golf is well positioned to capture momentum and run with it. By focusing on quality, innovation and inclusivity, Newton Golf plays a vital role in welcoming new players and nurturing their development. As the number of on-course beginners continues to set new records, Newton Golf is committed to ensuring that the game’s growth is both sustainable and enjoyable for generations to come.

For more information, visit www.NewtonGolfCo.com.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

• WLDS recently launched an initiative to develop advanced human-machine interfaces specifically designed for military scenarios
• Wearable Devices operates at the nexus of neural sensing, AI and user experience design
• These developments underscore the company’s broader mission: To redefine human-computer interactions by harnessing AI-powered, intuitive neural input systems

Wearable Devices (NASDAQ: WLDS) is extending the boundaries of human-machine interaction, taking its neural interface technology from consumer input device to the front lines of defense innovation. Known for creating AI-powered, gesture-controlled wearables that let users interact without touch, the company is now developing advanced, touchless control systems for military tactical applications, opening the door to a new era of precision, speed and safety in high-stakes environments (ibn.fm/pNRjO).

The company recently launched an initiative to develop advanced human-machine interfaces specifically designed for military scenarios. This project reflects the company’s strategy of extending its proprietary neural sensing platforms, exemplified by consumer-focused products such as the Mudra Band and Mudra Link, into high-stakes environments that demand precision, reliability and hands-free control.

Wearable Devices have already solidified their role as an innovator in AI-enabled wearables. The company’s proprietary neural input technology converts subtle wrist signals into seamless control mechanisms for AR, XR, and smart devices as well as other platforms. The company’s products — Mudra Band for iOS and Mudra Link for Android — allow users to interact naturally through gestures without touch.

Wearable Devices operates at the nexus of neural sensing, AI and user experience design. The company is also ramping up efforts in health, wellness and predictive analytics through its Large Motor Unit Action Potential Model (“LMM”) platform that brings physiological monitoring to mainstream wearables. With the U.S. Department of Health and Human Services endorsing wearables for real-time health insights (ibn.fm/iP2AB), Wearable Devices positions itself to serve both enterprise and healthcare markets. The company’s R&D roadmap clearly spans not just feature-rich consumer wearables but also influential domains such as defense, enterprise situational awareness and medical informatics.

These developments underscore Wearable Devices’ broader mission: To redefine human-computer interactions by harnessing AI-powered, intuitive neural input systems. WLDS’s product ecosystem enables hands-free control, immersive computing and gesture-based engagement across environments ranging from gaming and XR to tactical operations and health monitoring.

Wearable Devices combines proprietary sensors, advanced AI algorithms and silicon-based neural processing in its wrist-worn technologies. Its approach is grounded in expanding use cases, moving from Apple Watch control with Mudra Band to universal BLE device compatibility with Mudra Link, all while developing tools such as AI-powered gesture personalization and enterprise dev kits (ibn.fm/liOLh).

As the AI wearables market continues its meteoric rise, expected to exceed $260 billion by 2032, Wearable Devices is strategically diversifying its applications, from retail and productivity to immersive experiences and tactical deployment (ibn.fm/XDiom). With the latest military interface project and patent expansions, the company demonstrates not only what its technology can do but also where it can go.

For more information, visit www.WearableDevices.co.il.

NOTE TO INVESTORS: The latest news and updates relating to WLDS are available in the company’s newsroom at https://ibn.fm/WLDS

The NECANN New Jersey Cannabis Convention, in association with 420NJevents, will be held at the Atlantic City Convention Center, Atlantic City, on September 5-6, 2025. This year’s event is expected to welcome over 5,000 industry attendees with 200 exhibitors showcasing their unique cannabis business ideas and products.

A special element added to the event this year is the NECANN Cup, a third-party evaluation of cannabis and cannabis products. NECANN Cup is New England’s largest cannabis competition where the best cannabis products are recognized and awarded.

This NECANN New Jersey Cannabis Convention presents a phenomenal business opportunity for cannabis buyers, dealers, cultivators, and brands. Over 200 exhibitors including cultivators, retailers, distributors and ancillary businesses will gather at this always popular event, the largest gathering of licensed operators covering the mid-Atlantic markets.

The NECANN New Jersey Cannabis Convention has grown its networking and business connections since the first event in 2019. A not-to-miss event, the convention is attended by top industry leaders and investors in the East and beyond. As New Jersey has emerged as a thriving cannabis hub, the NECANN Convention brings in immense business and investment avenues for the regional cannabis trading community.

Local businesses, growers, and entrepreneurs set up exhibitor booths to showcase their innovative products and services, and attendees have the opportunity to interact and engage directly with industry thought leaders, gaining answers to important questions. Experts will share insights on the latest trends, technologies, policies, and regulations, in the cannabis industry. Participants and enthusiasts will discover new products while enjoying all the other unique experiences, including the celebration of the NECANN Cup, offered at this major event.

The NECANN New Jersey Convention boosts the area’s cannabis business community by providing an interactive platform for business and networking, as local traders connect with investors who are on the lookout for investment opportunities.

To learn more, please visit https://ibn.fm/lgjSX.

• Bolivia is the world’s fourth-largest silver producer, yet much of its mineral-rich territory remains unmapped.
• Less than 10% of Bolivia’s silver-rich mineral belt has undergone modern exploration.
• New Pacific Metals owns two of the world’s largest undeveloped silver projects: Silver Sand and Carangas.
• The company’s projects could potentially produce more silver annually than many of the current global producers.

Bolivia’s silver story is centuries old, but for much of the modern era, its richest regions have seen limited modern exploration. New Pacific Metals (NYSE American: NEWP) (TSX: NUAG), a Canadian mineral exploration and development company, is positioning itself to change that. With less than 10% of the country’s silver-rich mineral belt explored using current high-tech techniques, significant opportunities remain for new discoveries. New Pacific is advancing what could become one of the largest new silver districts in the world.

According to the US Geological Survey, Bolivia ranked fourth in global silver production in 2024, accounting for 5% of world output (https://pubs.usgs.gov/periodicals/mcs2025/mcs2025-silver.pdf). Despite that ranking, more than 60% of the national territory remains unmapped or unexplored, leaving significant untapped potential. This is especially notable in the Andes and highlands, where geological conditions point to large deposits of base and precious metals (https://ibn.fm/wmpNL).

New Pacific’s flagship Silver Sand and Carangas projects are discoveries made within the last five years and represent two of the world’s largest undeveloped silver deposits. Economic studies completed in 2024 indicate that, combined, Silver Sand and Carangas have the potential to produce around 18.5 million ounces of silver per year—more than many established producers generate. 

The scale of the opportunity is underscored by Bolivia’s mining history. The Cerro Rico mine in Potosí, often cited as the richest silver deposit ever discovered, produced enough metal to bankroll much of the Spanish Empire. The deposit’s total silver endowment is estimated at 3.7 billion ounces. However, aside from historic mining centers like Cerro Rico, much of Bolivia’s geology has yet to be systematically examined with modern exploration tools.

New Pacific Metals’ shareholder base offers an additional point of interest. Silvercorp Metals (NYSE-A/TSX: SVM), a Canadian mining company producing silver, gold, lead, and zinc with a long history of profitability, holds a 28% stake in New Pacific, while Pan American Silver (NYSE: PAAS) (TSX: PAAS), one of the world’s largest primary silver producers, owns 12%. These strategic positions suggest that both companies see potential in developing the Bolivian assets, either directly or through eventual acquisition.

New Pacific’s strategy is to advance its projects to “shovel ready” status. Both Silver Sand and Carangas have manageable initial capex, small enough that New Pacific could conceivably build them itself, or alternatively attract interest from other suitors seeking to expand their silver output. With primary silver projects in short supply globally, high-grade deposits are increasingly valuable, in a market driven by rapidly increasing demand.

Industrial demand for silver reached a record 655 million ounces in 2023, representing an 11% increase from the previous year, and this surge is expected to continue, especially as a result of solar industry demands (https://ibn.fm/bHaMB). The industry is anticipated to require 273 million ounces of silver annually by 2030, and by 2050, global renewable energy infrastructure, including solar, is projected to consume more silver than has been mined in the past 500 years combined.

This further underscore the importance of developing silver-rich assets such as New Pacific’s projects in Bolivia. The country’s combination of historic richness and modern underinvestment presents one of the few remaining “frontier” exploration opportunities. For investors looking at long-term exposure to silver, New Pacific therefore offers a play on both resource potential and the reawakening of one of the world’s high-potential historic mining regions.

For more information, visit the company’s website at www.NewPacificMetals.com/welcome.

NOTE TO INVESTORS: The latest news and updates relating to NEWP are available in the company’s newsroom at https://ibn.fm/NEWP

• Lantern Pharma has publicly launched predictBBB.ai (TM), its AI-driven module for predicting small-molecule blood-brain barrier permeability.
• The tool achieves 94% prediction accuracy, with 95% sensitivity and 89% specificity, based on real-time ensemble machine learning.
• Powered by Lantern’s vast molecular features data lake and ensemble algorithms, the platform sets a new computational benchmark for CNS drug discovery.
• Lantern hosts additional predictive and analytical modules in development, leveraging its large-scale data infrastructure and algorithmic approach.
• The tool is publicly accessible through a freemium model, aiming to drive adoption, strategic partnerships, and accelerate CNS therapeutic development.
• Lantern Pharma subsidiary Starlight Therapeutics secures FDA IND clearance for its Phase Ib/IIa trial combining STAR-001 (“LP-184”) and spironolactone in recurrent glioblastoma multiforme.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has introduced predictBBB.ai(TM), a publicly available AI module designed to predict blood-brain barrier (“BBB”) permeability for small-molecule drugs with unprecedented speed and accuracy (https://ibn.fm/9RZYo).

Crossing the BBB remains one of the pharmaceutical industry’s most persistent challenges. Traditionally, only 2-6% of small molecules manage to penetrate this critical barrier. Lantern Pharma aims to transform this bottleneck by providing researchers with real-time predictions powered by billions of molecular data points drawn from its proprietary molecular features data lake.

The module’s performance metrics speak for themselves: 94% accuracy, 95% sensitivity, and 89% specificity, all achieved through an ensemble of machine learning models including logistic regression, random forests, SVMs, and deep neural networks.

By claiming five of the top eleven slots on the Therapeutic Data Commons leaderboard, Lantern Pharma demonstrates clear technological superiority over academic and commercial competitors.

Lantern is offering predictBBB.ai(TM) via a freemium model, granting open access to foundational BBB prediction tools while positioning more advanced functionality for partnership-driven deployment. This strategy aims to foster early adoption among pharma and academia, leading to longer-term collaborations.

“We’re witnessing unprecedented demand for AI-driven solutions that deliver measurable impact on pharmaceutical development success rates,” said Panna Sharma, Chief Executive Officer of Lantern Pharma. “Our BBB prediction module establishes the foundation for deeper partnerships that leverage our comprehensive platform capabilities to accelerate therapeutic development across diverse disease areas while maintaining the highest standards of scientific rigor and predictive accuracy.”

The module’s architecture is built on real-time processing of SMILES molecular input via ensemble algorithms, underpinned by advanced feature engineering and synthetic data augmentation. Lantern plans to expand its suite of AI modules to cover a wider range of drug development properties, leveraging the same robust data and architecture. Predicting BBB permeability early can significantly reduce costly failures in CNS drug development, where failure rates and costs remain critically high. Lantern’s tool could lower risk and timeline for brain cancer and neurological therapies 

“This public release has the potential to be a paradigm shift in how pharmaceutical organizations and researchers approach CNS drug development,” Sharma added. “Our technology transforms what has historically been one of drug discovery’s critical bottlenecks into a competitive advantage. By democratizing access to industry-leading BBB prediction capabilities through our freemium approach, we’re enabling researchers worldwide to accelerate therapeutic development while building strategic partnerships that drive innovation.”

The release aligns with Lantern’s broader RADR(R) AI platform, which integrates this BBB module alongside other predictive tools for molecular and clinical performance, collectively enabling more efficient therapeutic development, especially in CNS and oncology domains.

Complementing this technological advance, Lantern Pharma’s subsidiary Starlight Therapeutics secured Food and Drug Administration IND (investigational new drug) clearance for its Phase Ib/IIa trial combining STAR-001 (“LP-184”) and spironolactone in recurrent glioblastoma multiforme (“GBM”); a study enabled by Lantern’s AI-driven RADR(R) platform (https://ibn.fm/PScS6). The company is currently undergoing a Phase Ia trial to determine dosing, safety, and the maximum tolerated dose across various solid tumors, including GBM.

Starlight is planning to initiate the Phase Ib/IIa trial between late 2025 and early 2026, with the goal of assessing the tolerability, preliminary efficacy, and safety of the combination therapy in individuals with recurrent GBM.

For more information, visit the company’s website at www.LanternPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

• IzoView Breast CT targets aggressive market displacement with up to 67% lower pricing than competing breast CT systems, positioning at $500K versus competitors priced up to $1.5 million
• True 360-degree 3D imaging without compression positioned to bridge the clinical gap between standard screening and MRI, offering 100x greater spatial resolution than MRI at significantly lower cost
• Platform approach enables 14 potential future indications across screening, diagnosis, monitoring, and treatment planning through software upgrades, creating scalable revenue expansion without hardware replacement

Every year, outdated imaging technologies underperform for the roughly half of women undergoing breast cancer screening who have dense breast tissue. Dense breast tissue creates a fundamental imaging challenge in compression-based imaging, like mammography, where overlapping structures can mask cancers, potentially delaying diagnosis when cancers are small and in their most treatable stages. This limitation represents an $8 billion annual burden in follow-up procedures, repeat imaging, and unnecessary interventions driven by inconclusive results from current screening technologies.

The breast imaging landscape has remained largely static for decades, dominated by compression-based mammographic systems never designed specifically for breast cancer the detection requirements of half of women undergoing screenings. While digital enhancements like tomosynthesis have provided incremental improvements, the fundamental constraints of 2D imaging and breast compression continue to limit diagnostic confidence, particularly in dense tissue cases.

This technological plateau occurs against rapidly advancing computational capabilities, artificial intelligence integration, and precision manufacturing that enable entirely new approaches to medical imaging. Current diagnostic pathways often require multiple imaging modalities, callback procedures, and complex workflows that consume significant resources while potentially delaying definitive diagnosis.

Izotropic (CSE: IZO) (OTCQB: IZOZF) is developing this type of transformational approach through its IzoView Breast CT Imaging System, designed to disrupt established imaging categories through projected superior clinical performance at competitive pricing.

Competitive Positioning Targets Market Displacement

Izotropic’s strategic positioning reflects sophisticated understanding of how disruptive medical technologies achieve market penetration. As Tomosynthesis (“DBT”) is becoming increasingly popular for screening, IzoView works alongside DBT, with its images read in conjunction with DBT scans, to serve higher-value segments such as dense breast imaging, where cancer risk is elevated and current technologies fall short.

The competitive analysis reveals significant pricing advantages over existing breast CT systems. With competing devices priced up to USD $1.5M, IzoView’s target price of $500K represents up to a 67% cost reduction that could accelerate adoption across imaging centers previously priced out of breast CT technology.

This pricing strategy positions IzoView to potentially displace multiple existing technologies simultaneously. The device targets replacement opportunities in ultrasound systems ($200K-$300K), contrast-enhanced mammography (~$420K), automated breast ultrasound ($200K-$300K), and molecular breast imaging (~$600K), while offering clinical capabilities approaching breast MRI performance at a fraction of the cost.

The clinical differentiation centers on IzoView’s true 360-degree 3D imaging capability without breast compression. Unlike tomosynthesis, which provides limited-angle 3D reconstruction, IzoView images the breast in its natural state with complete three-dimensional visualization. This approach eliminates tissue overlap masking while providing 100x greater spatial resolution than MRI systems.

The 10-second imaging session offers substantial workflow advantages over MRI (60+ minutes) while maintaining radiation doses comparable to 2-view mammography.

Platform Architecture Enables Scalable Value Creation

IzoView’s design as an upgradeable platform rather than a fixed-function device creates multiple value creation opportunities extending beyond initial capital equipment sales. The company has identified 14 potential future indications for IzoView in its current form, across five clinical areas: screening, diagnosis, monitoring, treatment planning, and personalized medicine.

This platform approach enables advanced capabilities delivery through software updates rather than hardware replacement, creating strong retention incentives for early adopters while generating recurring revenue opportunities. Healthcare facilities investing in IzoView can expand imaging capabilities over time without additional capital expenditure for core system replacement.

The modular engineering addresses practical deployment considerations that have limited competing breast CT system adoption. IzoView incorporates radiation self-shielding, eliminating specialized facility requirements that add installation cost and complexity. The patient-centered design focuses on comfort and accessibility, addressing common patient experience limitations with existing breast imaging technologies.

Izotropic’s exclusive worldwide licensing agreement with the Regents of the University of California provides foundational technology, while the developing patent portfolio focuses on integrated capabilities including image acquisition, data presentation, workflow integration, and artificial intelligence applications. Trade secret elements, including a proprietary deep machine learning image reconstruction algorithm provide additional competitive protection. 

Market Dynamics Support Disruptive Technology Adoption

The global breast imaging device market’s projected growth from $5.4 billion in 2024 to $8.69 billion by 2030, representing an 8.25% compound annual growth rate (“CAGR”). The U.S. market alone is forecasted to expand from $1.0 billion to $1.55 billion during the same period (7.57% CAGR). This growth is being driven by increased demand for advanced diagnostic capabilities, particularly in dense breast imaging applications, as well as rapid adoption of high-growth modalities such as digital breast tomosynthesis, molecular breast imaging, and breast MRI.

IzoView’s initial indication as an adjunct to tomosynthesis with contrast enhancement for dense breast screening in asymptomatic women positions the device to capture share from multiple existing categories while helping define the emerging next-generation breast imaging segment. This positioning addresses both clinical limitations and economic inefficiencies in current diagnostic pathways.

The economic value proposition addresses healthcare system cost pressures through potential consolidation of multi-step diagnostic workflows. Current pathways often require sequential imaging across multiple modalities (e.g., initial mammography, followed by tomosynthesis, ultrasound, and potentially MRI), each adding cost, time, and patient anxiety. IzoView’s comprehensive imaging capability in a single session could eliminate many sequential steps while providing superior diagnostic information.

The device’s positioning between tomosynthesis and MRI in both clinical capability and cost structure creates market opportunities across imaging centers that currently cannot justify MRI investments but require enhanced diagnostic capabilities beyond conventional mammography. This accessibility could drive rapid adoption across diverse healthcare environments.

Izotropic’s regulatory preparation includes FDA pathway clinical study design alignment, providing clear direction for pivotal study execution and market authorization. The completion of comprehensive business planning and financial modeling demonstrates preparation for post-approval market entry, while market education initiatives recognize that breakthrough medical technologies require awareness building alongside regulatory approval.

Transformational Potential at Market Inflection Point

Izotropic’s development of IzoView positions the company at the convergence of favorable market dynamics: growing demand for enhanced breast imaging, technological capabilities enabling superior diagnostic approaches, and economic pressures favoring comprehensive single-modality solutions over multi-step diagnostic pathways.

The combination of significant clinical advantages, competitive pricing, platform scalability, and comprehensive commercialization preparation creates a foundation for potentially transformational market impact. IzoView could establish a new standard for how breast cancer detection integrates advanced imaging technology with practical healthcare delivery requirements.

For more information, visit the company’s website at www.IzoCorp.com

NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF

Informa, a company on a mission to provide professionals and commercial customers with access to extraordinary people and exceptional insights, is proud to announce FinovateFall, coming this September. The industry-leading event will deliver cutting-edge fintech demos, expert insights, and offer high-impact networking opportunities. Held at The Marriott Marquis Times Square, New York, this event will provide attendees with the opportunity to discover innovative fintech solutions that banks can utilize today, while connecting with senior-level experts who can help them plan for the future.

FinovateFall will feature a number of themes, including payments, open banking, anti-fraud and security, financial inclusion, SME/SMB banking, cryptocurrencies, and stablecoins. It is estimated that over 2,000 senior decision-makers, 1,000 banks and investors, and 475 financial institutions, will be in attendance, making it the go-to event for anyone in this space or with an interest in learning more about this industry.

Some of the speakers at the event will include Michelle Tran, Founder of NYC Fintech Women; Sarah Biller, Co-Founder of Fintech Sandbox; Sherry Wu, CTO at the University of Michigan Credit Union; and Pam Hannett, VP at Liberty Bank. There will also be a keynote address by Beth Haddock, a Board Member and Global Policy Lead at stablecoin Standard, discussing how stablecoins are poised to reshape banking in 2025.

In addition, the event will also announce the winners of the Finovate Awards on September 9, 2025. The awards recognize the fintech industry and its companies that are driving innovation in the fintech sector. It celebrates individuals who have been at the forefront of bringing new ideas to life. In total, 30 individuals in fields such as alternative investing, financial inclusion, UX/CX, lending, and payments, will be crowned.

Some of the judges at this year’s Finovate Awards include Shelley Pittman, a Partner at Advintro; Pradeep Muthukamatchi, a Principal Cloud Architect at Microsoft; Mary Wisniewski, an Editor-at-large at Cornerstone Advisors; and Jim Perry, a Senior Strategist at Market Insights.

To learn more about FinovateFall, please visit https://informaconnect.com/finovatefall

To learn more about Finovate Awards, please visit https://ibn.fm/yMuE6

• 50% joint venture interest in Ambler Metals, which controls Alaska’s high-grade Upper Kobuk Mineral Projects in one of the richest copper-dominant districts globally
• $24.6 million in cash as of May 31, 2025, with Base Shelf Prospectus and $25 million ATM Program in place for future funding flexibility
• Ongoing development of Arctic and Bornite deposits, backed by agreements with local Alaska Native Corporation for collaborative exploration

Copper’s Strategic Role in Energy Transition

Global demand for copper is set to rise sharply over the next decade as electrification, grid modernization, and renewable energy accelerate. The International Energy Agency estimates that copper demand from clean energy technologies will more than double by 2040, driven by upgraded transmission infrastructure, and the buildout of electric vehicles, and wind and solar capacity.

With many of the world’s producing copper mines facing declining grades, exploration and development projects in stable jurisdictions are increasingly critical to meeting long-term supply needs. This dynamic places high-grade, North American copper districts like Alaska’s Ambler Mining District in a favorable position to attract investment and development capital.

A High-Grade, Copper-Dominant District

Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) holds a 50% interest in Ambler Metals LLC, a joint venture with South32 Limited, a globally diversified mining company. Ambler Metals owns 100% of the Upper Kobuk Mineral Projects (“UKMP”) in northwestern Alaska’s Ambler Mining District, a region recognized as one of the richest and most prospective copper-dominant areas globally.

The UKMP hosts both polymetallic volcanogenic massive sulphide (“VMS”) deposits, containing copper, zinc, lead, gold, and silver, and carbonate replacement deposits with high-grade copper and cobalt mineralization. The company’s primary development focus is on the Arctic VMS deposit and its exploration focus is on the Bornite carbonate replacement deposit.

The Arctic deposit features a feasibility-level resource, while Bornite contains a preliminary-economic-assessment-level resource with substantial growth potential for critical minerals. Together, they form the foundation of Trilogy’s long-term strategy to develop the Ambler Mining District into a premier North American copper producer.

Collaborative Approach with Local Stakeholders

An agreement with NANA Regional Corporation, Inc., an Alaska Native Corporation, provides a framework for exploration and potential development in cooperation with local communities. This partnership approach helps ensure that project development respects subsistence livelihoods while delivering economic benefits to the region.

Strong Balance Sheet and Flexible Funding Options

As of May 31, 2025, Trilogy reported $24.6 million in cash and $23.8 million in working capital – sufficient to fund its approved fiscal 2025 cash budget of $3.1 million.

In April 2025, the company filed a Base Shelf Prospectus in Canada and a corresponding shelf registration statement on Form S-3 in the U.S., allowing for the issuance of up to $50 million in various securities over the next two to three years.

On May 27, 2025, Trilogy announced the launch of an at-the-market equity program (ATM Program), enabling it to sell up to $25 million in common shares at prevailing market prices. Proceeds, if utilized, are expected to support the continued development of the UKMP and general corporate purposes.

Advancing Key Projects

Earlier this year, Trilogy completed the Bornite Preliminary Economic Assessment (“PEA”). The study delivered initial economics for the underground portion of the high-grade copper-cobalt deposit, demonstrating the potential for a 30-year mine-life when combining Arctic and Bornite.

While there has been a reduction in overall activities at the State of Alaska’s Ambler access project, a planned 211-mile road to connect the mining district to Alaska’s highway system, Trilogy and its partners continue to advance technical work on the core deposits in anticipation of future infrastructure solutions.

Well-Positioned for Copper Market Dynamics

With a 50% interest in one of North America’s richest undeveloped copper districts, Trilogy Metals is strategically positioned to benefit from tightening copper supply-demand fundamentals. Its high-grade resources, stable jurisdiction, and strong joint venture partnership provide a solid foundation for future development.

The company’s prudent cash management, combined with flexible capital-raising tools through its Base Shelf Prospectus and ATM Program, enhances its ability to fund project advancement while minimizing dilution.

As the global energy transition continues to reshape commodity markets, the combination of grade, jurisdiction, and scale at the Upper Kobuk Mineral Projects underscores Trilogy’s potential role in meeting the world’s growing copper needs.

For more information, visit www.TrilogyMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMQ are available in the company’s newsroom at ibn.fm/TMQ